Rhythm Pharmaceuticals (RYTM) Cost of Revenue (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Cost of Revenue data on file, last reported at $7.2 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $7.2 million, up 96.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.0 million (up 61.86% YoY), and the FY2025 annual result was $19.5 million, up 45.81% from the prior year.
• Cost of Revenue grew to $7.2 million in Q1 2026 per RYTM's latest filing, from $4.8 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $7.2 million in Q1 2026 and troughed at $230000.0 in Q1 2022.
• A 5-year average of $3.0 million and a median of $2.9 million in 2024 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue jumped 5650.0% in 2022, then advanced 17.14% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $1.0 million in 2022, then surged by 214.49% to $3.2 million in 2023, then climbed by 17.14% to $3.8 million in 2024, then grew by 26.8% to $4.8 million in 2025, then surged by 49.04% to $7.2 million in 2026.
• Business Quant data shows RYTM's Cost of Revenue at $7.2 million in Q1 2026, $4.8 million in Q4 2025, and $5.5 million in Q3 2025.